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A B S T R A C T
The interaction of nedaplatin drug with modified SiO2 (0 0 1) surfaces has been investigated within the fra-
mework of Density Functional Theory. Nedaplatin molecule is adsorbed spontaneously onto silica surfaces. Silica
surface prevents drug degradation allowing the chemical attachment without any impact on the drug structure
itself. The nedaplatin sorption is mainly governed by H-bonding interactions on hydrated and trimethylsilane-
functionalized surfaces, while the drug is major stabilized by NeO, OeO interactions and H partial dissociation
on dehydrated silica. The differences on the adsorption strength could be used in future studies to control the
drug release, developing delivery silica systems according therapy requirements.
1. Introduction
Cancer is contemplated the second reason of death after heart at-
tack. Different therapies have been applied to kill cancer cells such as
chemotherapy, which is the use of chemicals or drugs in order to deal
with cancer cells. Platinum-based drugs are the spine of chemotherapy;
they play a vital role in treating a variety of cancer. In the last four
decades, platinum-based anticancer drugs have been synthesized for
hope in find a new drug with higher efficacy.
The anticancer drug, cisplatin, (see Fig. 1 and Table 1), the first
platinum- based antitumor drug, uncovered in the late 1960s, has be
converted into one of the most useful agents to treat diverse kinds of
cancer [1]. Motive of their cytotoxic activity, cisplatin occupies a cen-
tral function. Nowadays, it has been applied in over half hundred
percent of cancer medication [2]. Cisplatin is one of the best effective
drugs against ovarian, testicular, lung, head, neck, and bladder cancers
[3]. Its activity is consequence of the development of stable DNA-Pt
complexes via intra-strand cross-links, obtaining the modification of the
structure of DNA, which stops replication and favors the apoptosis be-
ginning. In water, cisplatin is unstable and it must be dispensed in a
saline solution preserving the chemical neutrality indispensable for fast
diffusion in the cells. PteCl bond is stable barely if chloride con-
centration is elevated as in the blood. Nevertheless, research works
have been carried out with dissimilar results [4].
The efficacy and applicability of cisplatin drugs are limited by
severe systemic toxicities and drug resistance. The drug disadvantages
are very distressing on patients, such as nephrotoxicity and ototoxicity,
and different drug targeting and delivery strategies have been devel-
oped to reduce the deficiency of platinum-based chemotherapy [5].
Inspite of the wide anticancer applications of cisplatin, its therapeutic
efficacy is somewhat compromised by the occurrence of serious side
effects such as nausea, vomiting, nephrotoxicity as well as development
of resistance [6–8]. All those drawbacks have been an incentive to
scientists to overcome them and attempt different methods and in-
gredients in order to obtain better specificity to target the tumor cells
and not extend to other healthy cells. In recent times, a new discovery
has been published, which has become a very useful method in these
years. Gold nanoparticles, for instance, were tried in order to enhance
cytotoxic activity in bile acid cisplatin derivatives [9]. Cisplatin units
have also been attached to bile acids in order to make them more
biocompatible and target them better to colorectal cancers [10,11].
Nedaplatin, (see Fig. 1 and Table 1), a cisplatin analog, has been
developed in 1983 to provide a treatment with effectiveness similar to
that of cisplatin but to decrease the toxicities induced by cisplatin, such
as nephrotoxicity and gastrointestinal toxicity [12]. Nedaplatin was
selected because it produced better results than cisplatin in preclinical
studies. In vitro chemo sensitivity test suggested that nedaplatin has
similar or superior activity than cisplatin in cervical cancer [13]. The
official indications are head and neck, testicular, lung, oesophagal,
ovarian, and cervical cancer. Nedaplatin showed no advantage over
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cisplatin in objective response and overall survival, but nedaplatin was
less toxic. More thrombocytopenia was observed, but less leucopenia,
nephrotoxicity and gastrointestinal toxicity [14]. The combination ef-
fect of nedaplatin plus paclitaxel was significantly higher than that of
cisplatin plus paclitaxel or carboplatin plus paclitaxel in mice [15]. A
human lung cancer subline was established that was seven times more
resistant to gemcitabine. Treatment of mice with a combination of ne-
daplatin and gemcitabine showed increased inhibition of tumor evo-
lution. The anticancer activity of a combination of paclitaxel and ne-
daplatin against SK-OV-3 human ovarian cancer cells in animal models
was synergistic and superior to other combinations [15].
The optimization of the dosing and delivery schedule of platinum-
based anticancer drugs on silica carriers could potentially minimize
adverse effects while maintaining their efficacy [16]. The surface
properties of silica can be influenced by surface silanols. Silica surfaces
may be altered by removing surface silanol [17] or, instead, the surface
silanols may be changed by organic groups producing a hydrophobic
and non-polar surface [18–21]. The characteristics depend on the sur-
face added organic groups. In this way, surface functionalization could
improve adsorption and could optimize the carrier properties. Designed
properties can be achieved by fractional hydrophobisation [22] or by
using larger organic molecules that leave a higher density of surface
silanols. In the nanotechnology world, surface modification can be used
in biomedical applications including tissue engineering, chemical and
drug delivery, chemical and biochemical diagnostics, nano and micro
encapsulation for stabilisation, modification, and controlled release,
thin and nano-structured film formation, and advanced material fabri-
cation [23–25].
Therefore, it is important to develop novel effective tumor-targeted
drug delivery systems. The questions that need to be answered are
“what changes occur during surface modification and how do these
changes affects the surface properties and hence their interaction with
the adsorbed molecule?” This paper describes computational studies of
nedaplatin drug adsorbed on silica SiO2 (0 0 1) surface: hydrated, de-
hydrated and modified using a trimethylsilane (TMS). The obtained
results from these surfaces are compared. It is believed that a better
understanding of the surface properties of the silica modified adsorbent
will lead to many more applications. It is hoped that these results will
provide new insight into the medicinal nanomaterials.
2. Computational method
The density functional theory (DFT) method, implemented using the
Vienna Ab-initio Simulation Package (VASP) computational code
[26,27] including the dispersion interactions via Grimme's –D2 cor-
rection [28] is applied to study the nedaplatin adsoption on SiO2 (0 0 1)
surfaces.
Delle Piane et al. [29] were dedicated special attention to analyze
the role of dispersion interactions in the adsorption mechanism and
their relationship with H-bond interactions in silica surfaces. The re-
sults of their work highlight the lack of pure DFT methods to model
adsorption systems implying inorganic surfaces and drugs of moderate
size, due to the missing consideration for dispersion interactions. For
both hydrophobic/hydrophilic surface models, dispersion interactions
play a vital role in determining the characteristics of the silica-drug
system, and they are central for the hydrophobic surface. It was con-
firmed that a competition may exist between H-bonds and dispersion
interactions, with important structural and energetic importance for the
adsorption. Then, the inclusion of dispersive forces during the optimi-
zation highlights their role in determining the most stable geometry and
adsorption energy.
Significant effort has been spend in the progress of DFT methods
that can describe dispersion interactions in recent years and diverse
solutions have been suggested. Dispersion can be included either in the
form of an empirical [28,30,31] or with reduced empiricism at various
levels of precision and computer requires [32–35]. Different kinds of
dispersion corrections to DFT, semi-empirical or density based, gen-
erally improve the predicted binding energies and geometries, and
several methods supply very accurate results. In general, higher accu-
racy schemes are accessible but these are restricted to smaller system
sizes [36,37]. In particular, we have previously experienced that com-
putationally inexpensive Grimme's –D2 method properly provides the
geometries and interaction energies in silica systems [38,39].
Describing the electron exchange-correlation term is done with in
the generalized gradient approximation (GGA) in form of
Perdew–Burke–Ernzerhof (PBE) correction [40–45]. The relaxed atomic
configuration of each system is obtained when the force is smaller than
0.04 eV/Å on each atom. Since a high dense Brillouin zone sampling is
necessary for a better description of physical quantities,
Fig. 1. Chemical structure of platinum agents Reference for nedaplatin atoms (Table 2).
Table 1
Geometrical parameters (bond distance (r) in
Å, angle (θ) in degree) for cisplatin and ne-
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Monkhorst–Pack [46] block was set to 3× 3×1, which leads to con-
vergence of energy. To do kpoint convergence testing, it were run
several calculations, each using a different mesh and was found the
smallest kpoint value such that the calculated energy of our system was
not significantly different (see Fig. 2). Selecting an adequately dense
mesh of integration points is vital for the results convergence, and it is
one of the main objectives when performing convergence tests.
The ground state was found by a Methfessel-Paxton smearing of
0.2 eV [47]. The hydrated, dehydrated and TMS functionalized SiO2
(0 0 1) surface cells are made of 112, 96 and 125 atoms. A vacuum
space of 30 Å is used which ensures that the z-axis of the periodic su-
percell is great enough and no interaction are presented between ad-
jacent supercells. Lateral distance between molecules is to about 12 Å to
eliminate interactions between nedaplatin molecules and neighboring
supercells. The energy, the bonding and the electronic structure are
investigated using the concept of the Density of States (DOS) and the
Bader charge analysis [48].
Fig. 2. Covergence of BZ k-point sampling.
Fig. 3. Stable geometries for nedaplatin sorbed on the hydrated silica. (H-bonds
are indicated with dashed lines).
Fig. 4. Stable geometries for nedaplatin sorbed on the TMS-functionalized si-
lica. (H-bonds are indicated with dashed lines).
Fig. 5. Stable geometries for nedaplatin sorbed on the dehydrated silica. (H-
bonds are indicated with dashed lines).
Table 2
Partial charge on atoms for isolated and adsorbed nedaplatin (neda) drug on the
dehydrated (DS), hydrated (HS) and TMS-functionalized (FS) surfaces.
Atom Isolated neda Neda on HS Neda on FS Neda on DS
C1 3.1096 3.1263 3.2485 3.2843
C2 1.2666 1.2727 1.2362 1.2913
H3 0.9824 1.0270 0.9495 0.9178
H4 0.9857 0.9708 0.9820 0.8944
H5 0.0004 0.0006 0.0011 0.0002
H6 0.0003 0.0001 0.0011 0.0002
H7 0.0005 0.0002 0.0013 0.0003
H8 0.0003 0.0007 0.0022 0.0007
H9 0.0002 0.0011 0.0022 0.0004
H10 0.0004 0.0009 0.0015 0.0000
O11 7.3744 7.3325 7.3470 7.2388
O12 7.5966 7.5724 7.5740 7.4086
O13 7.8798 7.8788 7.8868 7.8654
Pt14 9.1661 9.1894 9.1848 8.5423
N15 7.8204 7.7910 7.8064 7.7354
N16 7.8162 7.7552 7.8035 7.1496
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3. Results and discussion
Several initial configurations are considered in order to find the
most favorable nedaplatin adsorption geometries on the SiO2 (0 0 1)
surfaces. Nedaplatin molecule presents polar atoms in it molecular
structure. Oxygen and nitrogen atoms present greater negative charge;
this implies that, the main electron density is located around these
atoms becoming sites potentially more favorable for electrophilic at-
tack. Carbon and hydrogen atoms possess neutral or positive charge
presenting active centers for nucleophiles. Platinum atoms present re-
gions with positive potential and therefore are susceptible to nucleo-
philic attacks. These atoms of the molecule are very likely to be re-
active. Therefore, we have selected different geometries in where these
atoms of nedaplatin are located towards the surface and have mapped
the location of the molecule on the silica surfaces, following different
rotation angles (polar and azimuthal, at steps of 20 degree) and ad-
sorbate translations at steps of 0.25 Å.
Firstly, we have analyzed the nedaplatin adsorption on the hydrated
silica. Upon full structural optimization, the obtained stable config-
urations are found; they are depicted in Fig. 3. As we can see, G1 and
G2 are the most stable. The molecule-surface interaction is produced
via two and three OeH bonds, respectively, the shortest distances are
1.73 Å, 2.70 Å (for G1), 1.53 Å, 1.77 Å and 1.83 Å (for G2). Nedaplatin
also adsorbs on silica surfaces through interaction between the nitrogen
atom of the molecule and the hydrogen atom of surface silanols. The
obtained adsorption energies for both minimum configurations are si-
milar. G3 and G4 geometries only present one H-bonding interaction
and they are lesser stables than G1 and G2. The obtained adsorption
energies for G3 and G4 configurations are less than −1.00 eV implying
a weak interaction between the silica and the drug. It seems that a
physisorption takes place when the molecule adopts G3 and G4 geo-
metries.
In the second stage, changes to the adsorption process when the
silica surface is functionalized with TMS silane, are analyzed (Fig. 4).
The resulting structure and relative size of the group together with
residual silanols at the surface can be observed. Upon optimization, two
stable configurations are found for nedaplatin on the functionalized
surface (see Fig. 4). In general, the molecule presents bigger adsorption
energies on the TMS modified surface than hydrated silica surface. Two
H-bonds are formed for both configurations. The OeH distances are
Fig. 6. Density of states (DOS) of nedaplatin-hydrated silica, isolated hydrated silica and isolated nedaplatin.
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2.69 Å and 2.62 Å for G1, while 2.19 Å and 1.91 Å were obtained for
G2. Nedaplatin is adsorbed on silica through oxygen weak interactions
with hydrogen of TMS group. These interactions appear less specific
and more distant than the hydrogen bondings formed on the hydrated
silica. Modification of the surface with silane modifier produces sur-
faces with silyl group coverage which generate a surface with a com-
pact organic group and a more closed surface in the modified zone. The
steric geometry impediment causes by TMS modifier reduce the mole-
cule possibility of adequately positioned on the surface and then the
energy is higher. Consequently, the change in the surface accessibility
directly affects the adsorption as well as the location of nedaplatin
molecule on the surface.
Finally, a drastic surface deshydratation produces noticeable
changes in the adsorption energy of nedaplatin. The energy is reduced
and more stability is presented, the minimum adsorption geometries
can be seen in Fig. 5. The nedaplatin adsorption is more favorable and
stronger on dehydrated silica than both hydrated and TMS- functiona-
lized silica. The interactions between the molecule and the dehydrated
surface are the following. An NeO interaction (d= 2.03 Å) and five
HeO interactions (d=1.0, 2.2, 2.3, 2.6, 2.9 Å respectively) are pre-
sented for G1. An OeO interaction (d=1.4 Å) and one H-bonding in-
teraction (d= 1.3 Å) is presented for G2. G3 presents five H-bonds in-
teractions (d=1.73, 1.88, 2.57, 2.78, 3.12 Å respectively) while G4
presents two OeH bonds (d=2.15 and 2.69 Å respectively). G5 pre-
sents an OeO interaction (d=2.61 Å) and five H-bonding interactions
(d=0.97, 1.82, 2.34, 2.38, 2.50 Å respectively). In addition, G1, G2
and G5 present partial dissociation of an H of nedaplatin that interacts
with silica surfaces via O superficial atoms. In general, the presence of
all the interactions justifies, in part, the smaller energies obtained for
these configurations.
In general, no significant changes are observed in the geometry of
nedaplatin during the interaction with all surfaces. This confirms that
silica surface can act as drug carrier and protect the drug from de-
gradation. The role of the surface is thus of a crucial importance on
drug adsorption, indeed it allows the chemical attachment without any
impact on the drug structure itself.
Electronic density is a very helpful tool to find sites of electrophilic
or nucleophilic reactions attack and correlate, in same way, charge
Fig. 7. Density of states (DOS) of nedaplaitn-hydrated silica, isolated hydrated silica and isolated nedaplatin.
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transfer to adsorption effectiveness. In order to compare, we have
performed the Bader charge analysis for the nedaplatin planar ad-
sorption (G1) on the hydrated, TMS-functionalized and dehydrated
surfaces. The aim of this analysis is to present a prediction of the
electron rearrangement when the molecule (with similar geometry –
planar) adsorbs on the different surfaces. Table 2 shows the charge on
individual atoms of nedaplatin molecule according to Bader space-
partitioning scheme (see reference of atoms in Fig. 1). Nedaplatin has
reactive atoms that facilitate the adsorption of the molecule on the si-
lica surface. It contains nitrogen and oxygen atoms, which could easily
be deprotonated/protonated, and some electrons exist in this molecule.
Electron density difference indicates that during adsorption is produced
a charge exchange and an electron density rearrange in agreement with
the new interactions. According calculations, the charge distribution
changes when the drug interacts with the surface and the changes on
atomic orbits takes mainly place in nedaplatin atoms bonded to sub-
strate. When nedaplatin absorbs on the hydrated surface, major changes
are observed on N atoms. This confirms the Nneda-Osurface interaction
that takes play in G1. When the molecule absorbs on the TMS-
functionalized surface, the changes are observed on H atoms of neda-
platin; these changes are small and an electron rearrangement manly
occurs. When nedaplatin absorbs on the dehydrated surface, the major
changes are observed on C, O, Pt and N atoms of nedaplatin. The partial
charges of atom reveal that H, O, Pt and N atoms of the anticancer drug
in the molecule-surface complex are more negative than those in the
isolated molecule. On the other hand, the C atoms of nedaplatin drug in
the complex are more positive than those in the isolated molecule. This
implies that, the total electron density is located around these atoms
that interact with the dehydrated surface. The electron population
analysis reveals that significant charge transfer occurs during the ad-
sorption processes; the charge is transferred from the drug to the de-
hydrated surface and vice versa strengthens the molecule-surface
bonding.
We have computed the density of states (DOS) of the system when
nedaplatin planar (G1) absorbs on hydrated (Fig. 6), dehydrated
(Fig. 7) and TMS functionalized (Fig. 8) surfaces. In addition, the
densities of states of the clean surfaces (without the adsorbed molecule)
and the isolated nedaplatin molecule are also shown in Figs. 6–8. There
Fig. 8. Density of states (DOS) of nedaplaitn-TMS functionalized silica, isolated TMS-functionalized silica and isolated nedaplatin.
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are bands associated with the interaction between nedaplatin and the
surface orbitals. The overlapping molecule-surface takes mainly play as
follows: from −25 to −18 eV and −14 to −2 eV (nedaplatin-hydrated
silica), from −25 to −18 eV and −14 to Fermi level (nedaplatin-de-
hydrated silica), from −24 to −20 eV and −15 to −2 eV (nedaplatin-
TMS functionalized silica). Dehydrated silica presents bigger changes in
the DOS spectrum compared with the other surfaces. New states appear
between −2 eV and Fermi level (see Fig. 7). Nedaplatin on the dehy-
drated surface mainly contributes with new states in the low part of the
band and a continuous population region can be seen near the Fermi
level. Consequently, electrons could be transferred more easily from the
valance level to the conducting level during the drug adsorption, this
also justify the enhance stability and the strongest interaction between
nedaplatin and the dehydrated silica.
4. Conclusions
One of the important applications of nanotechnology is in drug
delivery in particular, the targeted delivery of drugs. A proper under-
standing of adsorption behavior of drugs into the carriers is vital for
develop nanoscale drug delivery vehicles. In this work, the interaction
of nedaplatin drug with hydrated, dehydrated and TMS functionalized-
silica surfaces have been investigated.
By performing DFT calculations it is found that silica surface pre-
vents drug degradation allowing the chemical attachment without any
impact on the drug structure itself. The dehydrated silica is an efficient
carrier for nedaplatin drug due to the obtained appreciable adsorption
energies; whereas this drug weakly interacts with TMS functionalized-
silica and moderate adsorbs on hydrated silica. The stabilization of
nedaplatin is mainly governed by hydrogen bonding interactions on
hydrated and TMS fuctionalized- surfaces, while the drug is major
stabilized by NeO, OeO interactions and H partial dissociation on
dehydrated silica. The differences on the adsorption strength could be
used in future studies to control the drug release, according the opti-
mization dosing and the delivery schedule, developing targeting sys-
tems based on silica material for the potential pharmacological con-
trolled delivery of nedaplatin drug.
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